Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.62 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.56 |
| ▸ | GAA | P10253 | 8/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | GLA | P06280 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 6/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | FUBP1 | Q96AE4 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14008902 | 0.86 | KDM4E (0.49) | KDM4EL3MBTL1RXFP1ALDH1A1GAA | |
| SCHEMBL3266000 | 0.81 | KDM4E (0.44) | KDM4EL3MBTL1RXFP1ALDH1A1GAA | |
| SCHEMBL1593531 | 0.78 | ALDH1A1 (0.64) | KDM4EL3MBTL1RXFP1ALDH1A1GAA | |
| SCHEMBL13471700 | 0.78 | ALDH1A1 (0.60) | KDM4EL3MBTL1RXFP1ALDH1A1GAA | |
| SCHEMBL12568259 | 0.77 | ALDH1A1 (0.56) | KDM4EL3MBTL1RXFP1ALDH1A1GAA | |
| SCHEMBL12090639 | 0.77 | ALDH1A1 (0.51) | KDM4EL3MBTL1RXFP1ALDH1A1GAA | |
| SCHEMBL3743332 | 0.77 | ALDH1A1 (0.51) | KDM4EL3MBTL1RXFP1ALDH1A1GAA | |
| SCHEMBL5674583 | 0.75 | ALDH1A1 (0.58) | KDM4EL3MBTL1RXFP1ALDH1A1GAA | |
| SCHEMBL3603965 | 0.74 | ALDH1A1 (0.50) | KDM4EL3MBTL1RXFP1ALDH1A1GAA | |
| SCHEMBL6412508 | 0.74 | KDM4E (0.53) | KDM4EL3MBTL1RXFP1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7919626-B2 | Pyrazole compounds and uses thereof | HELICON THERAPEUTICS, INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-20110059981-A9 | New Pyridine Analogues V | ASTRAZENECA AB (SE) | 2011-03-10 | — | — | US | disclosed |
| US-20100137277-A1 | PYRIDINE COMPOUNDS AND THEIR USE AS P2Y12 ANTAGONISTS | ASTRAZENECA AB (SE) | 2010-06-03 | — | — | US | disclosed |
| US-20100069350-A1 | New Pyridine Analogues III | ASTRAZENECA AB (SE) | 2010-03-18 | — | — | US | disclosed |
| WO-2010005384-A1 | KETONE PYRIDINE ANALOGUES AND THEIR USE IN THE TREATMENT OF CARDIOVASCULAR DISORDERS | ASTRAZENECA AB (SE) | 2010-01-14 | — | — | WO | disclosed |
| WO-2010005385-A1 | 2-AMINO-6-ALKYL SUBSTITUTED PYRIDINE DERIVATIVES USEFUL AS P2Y12 INHIBITORS 308 | ASTRAZENECA AB (SE) | 2010-01-14 | — | — | WO | disclosed |
| US-20090318464-A1 | New Pyridine Analogues V | ASTRAZENECA AB (SE) | 2009-12-24 | — | — | US | disclosed |
| US-20090312368-A1 | Pyridine Analogues IV | ASTRAZENECA AB (SE) | 2009-12-17 | — | — | US | disclosed |
| US-20090286834-A1 | Pyridine Analogues VI | ASTRAZENECA AB (SE) | 2009-11-19 | — | — | US | disclosed |
| EP-2111400-A1 | PYRIDINE COMPOUNDS AND THEIR USE AS P2Y12 ANTAGONISTS. | AstraZeneca AB (SE) | 2009-10-28 | — | — | EP | disclosed |
| WO-2008004946-A1 | NEW PYRIDINE ANALOGUES | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | WO | disclosed |
| US-20080009523-A1 | New Pyridine Analogues IV | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
| WO-2008004942-A1 | NEW PYRIDINE ANALOGUES | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | WO | disclosed |
| WO-2008002247-A1 | NEW PYRIDINE ANALOGUES | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | disclosed |
| US-20070244088-A1 | New Pyridine Analogues II | ASTRAZENECA AB (SE) | 2007-10-18 | — | — | US | disclosed |
| EP-1083980-B1 | MODULATION OF MOLECULAR INTERACTION SITES ON RNA AND OTHER BIOMOLECULES | ISIS PHARMACEUTICALS INC (US) | 2007-03-21 | — | — | EP | disclosed |
| WO-2007008140-A1 | NEW PYRIDINE ANALOGUES | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | disclosed |
| US-6969763-B1 | Molecular interaction sites of interleukin-2 RNA and methods of modulating the same | ISIS PHARMACEUTICALS, INC. (US) | 2005-11-29 | — | — | US | disclosed |
| WO-2003091268-A1 | MOLECULAR INTERACTION SITES OF VIMENTIN RNA AND METHODS OF MODULATING THE SAME | ISIS PHARMACEUTICALS, INC. (US) | 2003-11-06 | — | — | WO | disclosed |
| WO-1999058947-A9 | MODULATION OF MOLECULAR INTERACTION SITES ON RNA AND OTHER BIOMOLECULES | ISIS PHARMACEUTICALS INC (US) | 2000-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009523-A1 | New Pyridine Analogues IV | P2RY12, P2RY4, P2RY11 | KDM4E 2808/4885L3MBTL1 4802/4885RXFP1 578/4885 |
| US-20090318464-A1 | New Pyridine Analogues V | P2RY12, P2RY11, P2RY13 | KDM4E 3080/4885L3MBTL1 4801/4885RXFP1 519/4885 |
| US-20090312368-A1 | Pyridine Analogues IV | P2RY12, P2RY4, P2RY11 | KDM4E 1243/4885L3MBTL1 4845/4885RXFP1 935/4885 |
| US-20100069350-A1 | New Pyridine Analogues III | P2RY12, P2RY11, P2RY1 | KDM4E 3901/4885L3MBTL1 4818/4885RXFP1 680/4885 |
| US-20070244088-A1 | New Pyridine Analogues II | P2RY12, P2RY1, P2RY11 | KDM4E 2897/4885L3MBTL1 4866/4885RXFP1 470/4885 |
| US-20090286834-A1 | Pyridine Analogues VI | P2RY12, P2RY6, P2RY11 | KDM4E 3490/4885L3MBTL1 4722/4885RXFP1 888/4885 |
| US-20110059981-A9 | New Pyridine Analogues V | P2RY12, P2RY11, P2RY13 | KDM4E 3080/4885L3MBTL1 4801/4885RXFP1 519/4885 |
| US-20100137277-A1 | PYRIDINE COMPOUNDS AND THEIR USE AS P2Y12 ANTAGONISTS | P2RY12, P2RY11, P2RY1 | KDM4E 4200/4885L3MBTL1 4823/4885RXFP1 563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.